Precipio (STU:TGK) Moat Score: 2/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TGK Precipio Inc STU:TGK
51 GF Score
Price €4.96
GF Value €2.26
! 2 Warning Signs
View Full Analysis

What is Precipio Moat Score?

Precipio STU:TGK 51 Moat Score is 2 as of Jul. 15, 2026. GuruFocus rates STU:TGK with a GF Score™ of 51/100 and a GF Value™ of €2.26. The stock has 2 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Precipio ranks better than 69.3% on this metric.

Precipio has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Precipio has No Moat: Precipio Inc operates in the diagnostic sector with limited market share and lacks significant intellectual property or cost advantages to establish a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Precipio might have No Moat - Very weak/transient advantages.

Precipio  (STU:TGK) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Precipio Moat Score Related Terms

STU:TGK vs QUCY, IDXG, BIOQ: Moat Score Comparison

For the Diagnostics & Research subindustry, Precipio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precipio Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Moat Score distribution charts can be found below:

* The bar in red indicates where Precipio's Moat Score falls into.


STU:TGK
51GF Score
Precipio Inc STU:TGK
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Precipio (STU:TGK) has a Moat Score of 2 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Precipio ranks #66 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 30.7%.
Is Precipio's Moat Score too high?
Precipio's current Moat Score is 2. Based on the distribution chart, Precipio ranks #66 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Precipio has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Precipio's Moat Score compare to QUCY and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #66 out of 215 companies for Moat Score. This puts Precipio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Precipio's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Precipio (STU:TGK) has a current Moat Score of 2. The stock's GF Value™ is €2.26, compared to a current price of €4.96 — trading 119.5% above its estimated fair value. The current Moat Score is 2. Precipio's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Precipio (STU:TGK), the current Moat Score is 2 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precipio (STU:TGK) Overvalued in 2026?

Based on GuruFocus' analysis, Precipio stock appears to be overvalued. The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.

Key valuation signals for STU:TGK:

  • Moat Score: 2
  • GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precipio Business Description

Other Exchanges PRPO:USA
Address 4 Science Park, 3rd Floor, New Haven, CT, USA, 06511
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score

Get the complete analysis for STU:TGK

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.96
Price
€2.26
GF Value